No Data
No Data
Jiangzhong Pharmaceutical's H1 Profit Rises 9%, Revenue Slides 8%
Summary of the semi-annual report of jiangzhong pharmaceutical in 2024
Jiangzhong Pharmaceutical Semi-Annual Report 2024
Chinares Pharma (03320.HK): jiangzhong pharmaceutical's net profit attributable to shareholders in the first half of the year was 0.489 billion yuan, a year-on-year increase of 8.66%.
On August 21, Chinares Pharma (03320.HK) announced that Jiangzhong Pharmaceutical's shares are listed on the Shanghai Stock Exchange. As of the date of this announcement, Jiangzhong Pharmaceutical is held by Chinares Medicine Group Limited (the 'Company'), along with its subsidiary, Chinares Jiangzhong Pharmaceutical Group Co., Ltd., and holds approximately 43.09% of the equity. The Group actually controls 26.09% of Jiangzhong Pharmaceutical, which is accounted for as a subsidiary of the Company. Jiangzhong Pharmaceutical's unaudited financial performance for the six months ending June 30, 2024. Jiangzhong Pharmaceutical achieved a revenue of 21 million in the first half of 2024.
Should Weakness in Jiang Zhong Pharmaceutical Co.,Ltd's (SHSE:600750) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Jiangzhong Pharmaceutical (600750.SH) plans to distribute 0.7 yuan per share in 2023, with ex-rights and ex-dividends on June 13.
Jiangzhong Pharmaceutical (600750.SH) announced its plan to distribute a cash dividend of 0.7 yuan per share for the 2023 fiscal year.
No Data